Grace Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | -9.1% | -9.1% | -7.6% |
| FY2023 | -62.4% | -62.4% | -53.6% |
| FY2024 | -20.8% | -20.8% | -17.5% |
| FY2025 | -14.4% | -14.4% | -13.3% |
| FY2026 | -12.2% | -12.2% | -11.7% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | -9.1% | -9.1% | -7.6% |
| FY2023 | -62.4% | -62.4% | -53.6% |
| FY2024 | -20.8% | -20.8% | -17.5% |
| FY2025 | -14.4% | -14.4% | -13.3% |
| FY2026 | -12.2% | -12.2% | -11.7% |